5 ETFs Targeting Sinners

So-called sin stocks have historically fallen into three main buckets: tobacco, alcohol and gambling. A fourth bucket, marijuana stocks, has developed over the past few years as recreational use of ...
Read Full Story »

Wall Street Has a New Strategy for Legal Marijuana – Whenever That Happens

With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged to complement the historically resilient characteristics of alcohol and tobacco. Cannabis stocks ...
Read Full Story »

What a Combined Allergan and Pfizer Might Actually Look Like

Allergan PLC (NYSE: AGN) has issued a press release that confirms some of the rumors floating in the market — it has been approached by Pfizer Inc. (NYSE: PFE) and ...
Read Full Story »

Large Companies With Fastest Revenue and Earnings Growth in 2015

This year is nearing the halfway mark and analysts are beginning to project their biggest winners and losers on the year. S&P Capital IQ recently released a report regarding the ...
Read Full Story »

American Airlines Replaces Allergan in S&P 500

American Airlines Group Inc. (NASDAQ: AAL) will be the newest addition to the S&P 500, taking the place of Allergan Inc. (NYSE: AGN). The change will occur after the close ...
Read Full Story »
buy sell

6 Stocks Will See Massive Buying and Selling on S&P Quarterly Rebalance

All indexes rebalance on a quarterly basis, as price movement constantly upsets the actual percentage that is supposed to be allocated. With the S&P 500 being the most influential index ...
Read Full Story »
generic drugs

As Valeant Ups Salix Buyout, Will Endo Come Back?

Monday morning, Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) both announced that they had entered into an agreement on their plan to merge based on ...
Read Full Story »
Dow Chemical logo

UBS Makes Big Changes to Equity Focus List For March

The higher the markets go, the more the major Wall Street firms are becoming content to really start taking some profits off the table and shifting allocations to stocks that ...
Read Full Story »

Is the Actavis $21 Billion Bond Sale Just the First?

Generally speaking, when one company offers to buy another for $66 billion, the acquiring company has to borrow money in order to pay up. That is what Actavis PLC (NYSE: ...
Read Full Story »

UBS Quality Growth at a Reasonable Price Stocks Beating the S&P 500

The rage for the past six years as the market has rocketed back from the depths of the 2008 subprime real estate collapse has been indexing. The basic tenet is ...
Read Full Story »
health care

Merrill Lynch’s Top Health Care Stock Picks for 2015

Merrill Lynch released its report looking forward to 2015 and which stocks it believes will outperform in the health care sector. In 2014, many of these same companies had very ...
Read Full Story »

9 Big Stocks That Doubled in 2014

The S&P 500 index has gained just over 12% in the past 52-weeks, a good effort, but far below the 32% return in 2013 and not quite up there with ...
Read Full Story »
Pfizer logo

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it ...
Read Full Story »
Botox injection

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Botox maker Allergan Inc. (NYSE: AGN), which has fended off offers up to about $173 per share from Valeant Pharmaceuticals International Inc. (NYSE: VRX), announced Monday morning that it has ...
Read Full Story »

Deutsche Bank’s U.S. Stock Selection Best Buy Ideas

As the rally rolls on toward the holiday season, many of the Wall Street firms we cover at 24/7 Wall St. are pulling out their best stock ideas in hopes ...
Read Full Story »